With pharmacare, drug pricing reforms and other changes on government agendas, plan sponsors face a shifting environment for their drug plans. What should they expect? Participants at the Face to Face Drug Plan Management forum in Vancouver got a primer on some of the issues. The conference, which took place on May 1 at the Fairmont Waterfront Hotel in Vancouver, also tackled some of the hot topics in drug plans, such as pooling, biosimilars and medical marijuana.
Here are the highlights of the sessions:
Breaking down the cost drivers: Deep dive shows 4.9% predicted rise for drug plans over three years
Understanding private plans’ past cost drivers can help to predict future growth rates in drug spending, according to Brad Millson, principal for health access and outcomes at IQVIA Inc.
Read more
Assessing the impact of government policies, reforms on private payers
With governments having announced a number of changes related to pharmaceutical policy, plan sponsors are facing a shifting environment for their drug plans.
Read more
Panel discussion: Hot topics in drug plan management
From drug pooling to medical marijuana, plan sponsors have a number of issues to keep track of when it comes to their benefits plans. At the Face to Face Drug Plan Management forum in Vancouver this month, a panel of experts tackled some of the hot topics the industry is thinking about.
Read more
From pharmacare to PMPRB reforms: The changing landscape for private plans
With a number of government reforms and new policies in the works, plan sponsors may well wonder about the potential impact on private drug plans. With that in mind, Suzanne Lepage, a private health plan strategist, led a panel discussion on new government policies and programs in the works at the Face to Face Drug Plan Management forum that took place in Vancouver this month.
Read more